A phase II study of arsenic trioxide in the treatment of relapsed and refractory low-grade lymphomas.

被引：0
|
作者：
Furman, RR [1 ]
Sirulnik, A [1 ]
Kamalu, OO [1 ]
Brenner, RB [1 ]
Paciucci, PA [1 ]
Gabrilove, JL [1 ]
Waxman, S [1 ]
机构：
[1] Mt Sinai Sch Med, Div Hematol & Oncol, New York, NY USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4758
引用
收藏
页码：304B / 304B
页数：1
相关论文
共 50 条
  • [1] A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma
    Zhao, Hongli
    Sun, Guoxun
    Kong, Desheng
    Zhang, Yujing
    Shi, Wudan
    Zhao, Mingming
    Hong, Luojia
    Qiao, Zhenkui
    MEDICAL ONCOLOGY, 2015, 32 (03)
  • [2] A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma
    Hongli Zhao
    Guoxun Sun
    Desheng Kong
    Yujing Zhang
    Wudan Shi
    Mingming Zhao
    Luojia Hong
    Zhenkui Qiao
    Medical Oncology, 2015, 32
  • [3] FLUDARABINE IN RELAPSED LOW-GRADE NON-HODGKIN LYMPHOMAS - A PHASE-II STUDY OF THE GERMAN LOW-GRADE LYMPHOMA STUDY-GROUP
    POTT, C
    UNTERHALT, M
    SANDFORD, D
    MARKERT, H
    FREUND, M
    ENGERT, A
    GASSMANN, W
    HOLTKAMP, W
    SEUFERT, M
    HELLRIEGEL, K
    KNAUF, B
    NIEBERDING, R
    EMMERICH, B
    KOCH, P
    WORMANN, B
    HIDDEMANN, W
    BLOOD, 1993, 82 (10) : A575 - A575
  • [4] A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-hodgkin lymphoma
    Larson, BJG
    Waples, JM
    Pusateri, A
    Mendenhall, NP
    Lynch, JW
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (02): : 165 - 168
  • [5] Phase II trial of fludarabine phosphate combined with interferon alpha 2A for low-grade lymphomas.
    Lynch, JW
    Hei, DL
    Hudson, JK
    Staab, EV
    Braylan, RC
    Mendenhall, NP
    BLOOD, 1997, 90 (10) : 1538 - 1538
  • [6] A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia
    Litzow, Mark R.
    Lee, Sandra
    Bennett, John M.
    Dewald, Gordon W.
    Gallagher, Robert E.
    Jain, Vibha
    Paietta, Elisabeth M.
    Racevskis, Janis
    Rousey, Steven R.
    Mazza, Joseph J.
    Tallman, Martin S.
    HAEMATOLOGICA, 2006, 91 (08) : 1105 - 1108
  • [7] Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas.
    Sacchi, Stefano
    Marcheselli, Raffaella
    Bari, Alessia
    Liardo, Eliana Valentina
    Luminari, Stefano
    Merli, Francesco
    Lazzaro, Antonio
    Neri, Santo
    Carella, Angelo Michele
    Fragasso, Alberto
    Falorio, Simona
    Buda, Gabriele
    Musto, Pellegrino
    Dell'Olio, Matteo
    Baldini, Luca
    BLOOD, 2010, 116 (21) : 752 - 752
  • [8] Fludarabine combined with etoposide in the treatment of refractory low-grade lymphomas
    Badea, M
    Badea, D
    Genunchhe, A
    Petrica, C
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 155
  • [9] Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
    Vose, JM
    Wahl, RL
    Saleh, M
    Rohatiner, AZ
    Knox, SJ
    Radford, JA
    Zelenetz, AD
    Tidmarsh, GF
    Stagg, RJ
    Kaminski, MS
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) : 1316 - 1323
  • [10] Report of a phase II study of proteasome inhibitor Bortezomib (VELCADE™) in patients with relapsed or refractory indolent or aggressive lymphomas.
    Goy, A
    Hart, S
    Pro, B
    McLaughlin, P
    Younes, A
    Dang, N
    Fayad, L
    Romaguera, J
    Cabanillas, F
    Hagemeister, F
    Samaniego, F
    Wang, M
    Mesina, O
    Gilles, F
    Trehu, E
    Shenkein, D
    BLOOD, 2003, 102 (11) : 180A - 180A
12345